Treating Osteoporosis with Oestrogen or Testosterone
نویسنده
چکیده
A research from 1983 examined the necessary dosage of oestrogen in treatment of postmenopausal bone loss and showed patients to experience bone loss in doses up to 15 micrograms and bone gain in doses above 25 micrograms of oestrogen [6]. It’s therefore plausible to assume the likely effectiveness of testosterone treatment to Osteoporotic men and of oestrogen treatment to osteoporotic women post menopause.
منابع مشابه
Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women.
STUDY OBJECTIVE To compare oral and implanted oestrogens for their effects in preventing postmenopausal osteoporosis. DESIGN Non-randomised cohort study of postmenopausal women treated with oral or depot oestrogens and postmenopausal controls. SETTING Gynaecological endocrine clinic in tertiary referral centre. PATIENTS Oral treatment group of 37 postmenopausal women (mean age 57.5 years,...
متن کاملModification of Sex Hormones with RGD-Peptide: A Strategy of Improving HRT and Other Secondary Osteoporosis Therapy
In the time of transition from premenopausal state to postmenopausal state the capacity of ovary producing sex hormones including estrogens, progesterone and testosterone cuts down [1]. Due to the menopause the level of serum oestrogen dramatically decreases, which increases the production of bone-resorbing cytokines and osteoblasts and then increases the number and activity of osteoclast, ther...
متن کاملOsteoporosis in men: a cellular endocrine perspective of an increasingly common clinical problem.
Although it has been accepted that osteoporosis is common in women, only recently have we become aware that it is also widespread in men; one in twelve men in the UK have osteoporosis. In many cases, there are recognisable causes for their osteoporosis, but a significant proportion (approximately one third) of these men have idiopathic disease. A major problem is that these cases are difficult ...
متن کاملCardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
BACKGROUND Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated with oral oestrogen. METHODS In this multicentre, open-label, randomised, phase 2 trial, we enrol...
متن کاملEffects of Low-Dose Testosterone Undecanoate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Male Osteoporosis with Low Serum Testosterone
This prospective 2-year, single-center, randomized, placebo-controlled, open-label clinical trial was performed to evaluate the efficacy of low-dose testosterone undecanoate (TU) treatment on bone mineral density (BMD) and biochemical markers of bone turnover in elderly male osteoporosis with low serum testosterone. A total of 186 elderly male osteoporosis patients with low serum testosterone w...
متن کامل